Background: Heart failure is a complex and multifactorial disease that affects millions globally, posing significant challenges to healthcare systems.

The company shared interim results from an ongoing Phase II trial examining its recombinant antibody fusion protein.

In the first 22 months of a mavacamten REMS program, few patients needed a temporary interruption in treatment for LVEF below 50%.

With the growing trend of heavier cattle and carcass weights, packers are seeing higher rates of bovine congestive heart ...

Mina Makar highlights AstraZeneca's commitment to advancing heart failure research and innovative therapies, addressing ...

Alleviant Medical announced today that it brought in $90 million to fund the second pivotal trial of its atrial shunt ...

Much has changed since the 2013 document came out, with new information on pacing devices, techniques, and more.

"These findings reinforce the use of dapagliflozin, 10 mg, or other SGLT2 inhibitors when the therapeutic goal is to reduce ...

Benefiting from technological and conceptual groundwork and positive early data, gene therapies are advancing in the clinic ...

Atrial fibrillation, or A-fib, is an irregular heart rhythm that increases a person's risk of stroke, heart failure and even ...

The following is a summary of “Impact of sodium-glucose cotransporter 2 inhibitors on catheter ablation for atrial fibrillation in heart failure patients without type-2 diabetes,” published in the ...

Cytokinetics stock up as the company initiates patient enrollment in its mid-stage study of pipeline candidate, CK-586, for treating heart failure patients.